Carisma therapeutics announces nomination of first in vivo car-m development candidate for hepatocellular carcinoma under collaboration with moderna

Development candidate targets glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma nomination triggers a $2 million milestone payment to carisma philadelphia , june 27, 2024 /prnewswire/ -- carisma therapeutics inc. (nasdaq: carm) ("carisma" or the "company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of the first development candidate ("development candidate"), under its collaboration with moderna, inc. the development candidate is an in vivo car-m targeting glypican-3 ("gpc3") and is designed to treat solid tumors, including hepatocellular carcinoma ("hcc"), the most prevalent type of liver cancer and the fastest-rising cause of cancer-related death in the u.s. this nomination triggers a $2 million milestone payment to carisma. the nomination of this development candidate leverages carisma's expertise in engineering chimeric antigen receptor monocytes and macrophages ("car-m") with moderna's mrna and lipid nanoparticle platform to create a novel in vivo cell therapy for oncology.
CAR Ratings Summary
CAR Quant Ranking